Don't read too much in that m123. Just a wild guess based on nothing I have read. With Life putting up the funding till the end of the P2 I doubt delisting will happen. If PBT434 shows promise in Parkinsonian diseases, this could be a rocket. Even positive results from Fairpark could boost ATH IMO. From the Fairpark site "The results of the clinical trial are expected by June 2020" That trial is a good size study and results, could help ATH. http://www.fairpark2.eu/partners
ATH Price at posting:
2.4¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)